Impress’s €40m EIB Loan Adds a New Layer to Existing Venture Debt

Impress’s €40m European Investment Bank loan was secured on the company’s UK subsidiary months before the lender announced it. Two EIB charges were created on 2 July 2026, delivered to Companies House the next day, and remain outstanding alongside two Trinity Capital charges from 2024.

That chronology changes the financing story. Impress is not simply adding a public-backed growth loan to an equity-funded healthtech expansion. Its visible UK security trail shows a new EIB layer sitting beside private venture debt, after older Norgine and Sabadell charges were satisfied in January. The register does not establish drawdown, lender priority or the full collateral package, but it does make the debt stack economically relevant.

The loan was public in October, security was visible in July

The EIB announcement dated 27 October describes a €40m venture-debt loan to Impress. The loan is guaranteed by InvestEU and is intended to develop Impress’s clinical artificial-intelligence platform and support expansion in Germany, the Netherlands and the United Kingdom. The EIB says the business has more than 110 clinics and has treated more than 500,000 patients.

The public announcement arrived nearly four months after the security filings. On the Companies House charges register, charge 129578950005 and charge 129578950006 were both created on 2 July and delivered on 3 July. The person entitled on each is the European Investment Bank, and both are marked outstanding.

The timing is not proof that the full loan was drawn in July. It is evidence that the EIB’s legal security was already visible on the UK register before the growth plan became public. That distinction matters when a financing headline presents the loan as a new source of runway rather than as a secured layer in an existing capital structure.

The UK subsidiary carries the visible debt trail

The charge records belong to SMILE2IMPRESS LTD, company number 12957895, the UK subsidiary in the Impress group. The operating story is broader: the principal Spanish entity is SMILE2IMPRESS S.L. (Sociedad Unipersonal), established in Barcelona in 2019. The public filings do not, by themselves, describe the group’s full guarantee chain or show which entity ultimately receives every euro of the EIB facility.

The UK record nevertheless gives a precise sequence of lender exposure:

The same register shows two charges created on 29 October 2024 for Trinity Capital Inc. Both remain outstanding. The older charges that named Sabadell Venture Capital and Norgine Ventures Fund I S.C.A. are the ones marked satisfied on 16 January 2026. The result is a visible change in lender mix: earlier security was released, Trinity remained, and EIB security was added before the announcement.

Two lender layers remain outstanding

The public charge summaries do not support a ranking conclusion. The summary for charge 129578950006 begins “All current and future real property and intellectual...” while the summary for 129578950005 has no applicable brief description. The filing history identifies the two underlying registration PDFs as 49 and 80 pages, but the public index does not supply the intercreditor terms, covenants, drawdown schedule or complete security definitions.

That leaves a narrow but important finding. The EIB and Trinity are both visible as current charge holders on the same UK subsidiary. It is not safe to call the EIB senior, first-ranking or fully secured ahead of Trinity without the instruments and any priority agreement. It is equally unsafe to treat the EIB facility as an unsecured corporate loan simply because the announcement focuses on artificial intelligence and international growth.

The distinction is familiar in private-market analysis. StrollMe’s hybrid fleet financing separates a growth plan from the secured and operating obligations that make the plan financeable. Cognitive Credit’s capital stack similarly shows why the headline amount is only one part of the economic structure. Impress’s filings add a lender chronology to an announcement that otherwise reads like a straightforward expansion story.

Equity funded the scale-up before debt extended it

Cinco Días reports that Impress had raised about €250m across five equity rounds before the EIB facility. Its independent report describes the company as preparing to expand in northern Europe and says the 2024 round was €110m. Public funding histories use different amounts for some earlier rounds, so the defensible description is “about €250m reported across five equity rounds,” not a reconstructed cap table or exact fully diluted total.

The sequence now visible is therefore:

This is why the €40m should not be read as a simple substitute for equity. It extends a capital base that already includes private debt, and the register shows that the extension was documented through security over the UK subsidiary. The commercial consequence is not necessarily distress or refinancing pressure. It is that the expansion plan now sits inside a multi-lender structure whose terms will matter as Impress adds clinics, develops its AI platform and enters new markets.

InvestEU changes public exposure, not proven priority

The InvestEU guarantee is a material part of the EIB’s public framing. It helps explain why a European public bank is supporting a venture-debt facility for clinical AI and international expansion. It does not answer the private-law questions created by the charge register. A guarantee can alter who bears part of a credit loss without telling outside readers whether EIB or Trinity ranks first against a particular asset, claim or enforcement scenario.

That distinction protects against two opposite overstatements. The facility should not be described as ordinary unsecured runway when two EIB charges are outstanding. But it should not be described as first-priority public capital, fully drawn debt or a claim over every clinic and item of intellectual property when the public charge summaries do not establish those points.

The EIB release and Cinco Días both emphasise the platform, the clinic network and expansion in Germany, the Netherlands and the UK. Those are the operating uses of capital. The Companies House record adds the financing mechanism: two EIB registrations alongside Trinity, after two older lender charges were satisfied.

The next documents are the intercreditor terms and Spanish records

The public evidence supports a specific conclusion and a specific watchpoint. Impress’s €40m EIB loan was legally secured months before its announcement, adding two outstanding EIB charges to an existing Trinity debt layer. Older Norgine and Sabadell security had been satisfied in January. The chronology is high-confidence; the economics of priority, drawdown and collateral remain unresolved.

The next decision-changing records are the two EIB charge instruments, any intercreditor or priority agreement with Trinity, and the Spanish financing and shareholder documents for SMILE2IMPRESS S.L. Those materials would show whether the UK security is a group-wide package, how the lenders share collateral, and whether the facility was drawn in full or in stages. Until they are available, the defensible reading is not “Impress has €40m of clean growth runway.” It is “Impress has added a public-bank security layer to a continuing venture-debt stack while it scales a heavily equity-funded business.”

Sources

• EIB announcement of the €40m Impress loan
• SMILE2IMPRESS LTD charges register, Companies House
• SMILE2IMPRESS LTD filing history, Companies House
• Cinco Días report on the loan and equity history